Breadcrumb

Breadcrumbs

Press Releases

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to mediainquiries@dsi.com. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

From To
Date Title
2018.12.03
Comprehensive Analyses from Pivotal Phase 3 QuANTUM-R Study Demonstrate Consistent Overall Survival ...
PDF (249 KB)
2018.11.27
Daiichi Sankyo and Roche to Collaborate on New HER2 Low Companion Diagnostic Test
PDF (239 KB)
2018.11.21
FDA Grants Priority Review for Daiichi Sankyo’s New Drug Application for FLT3 Inhibitor Quizartinib ...
PDF (246 KB)
2018.11.05
EMA Validates and Grants Accelerated Assessment of Marketing Authorization Application for Daiichi ...
PDF (245 KB)
2018.11.01
Daiichi Sankyo to Present Data from AML Franchise Including FLT3 Inhibitor Quizartinib at ASH Annua ...
PDF (231 KB)
2018.10.25
Daiichi Sankyo Announces Clinical Research Collaboration with Merck KGaA, Darmstadt, Germany and Pf ...
PDF (182 KB)
2018.10.23
Daiichi Sankyo, Inc. Publishes Second Edition of Pain Trends Report
PDF (211 KB)
2018.10.21
Daiichi Sankyo Presents Updated Results of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with ...
PDF (193 KB)
2018.10.18
Daiichi Sankyo Initiates Phase 1 Study of AXL Inhibitor DS-1205 in Patients with EGFR-Mutated Metas ...
PDF (186 KB)
2018.10.17
Daiichi Sankyo Submits Application in Japan for FLT3 Inhibitor Quizartinib for Treatment of Patient ...
PDF (286 KB)
Showing 21 - 30 of 47 results.

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...